在"健康中国2030"战略指引下，国产高端医疗器械正加速突破技术壁垒，向全球产业链中高端迈进。深 耕心血管精准介入领域的深圳北芯生命科技股份有限公司（简称"北芯生命"），十年来始终以"用创新 和品质改善生命健康"为使命，成功打破海外技术垄断，在商业化进程中展现强劲韧性，以硬核研发实 力，为全球心血管疾病诊疗贡献"中国方案"。 十年磨一剑 聚焦"卡脖子"难题 过去，冠脉功能学和腔内影像学精准诊疗器械市场长期被进口产品垄断，血流储备分数（FFR）系统、 冠脉血管内超声（IVUS）系统等关键设备依赖进口，存在价格高昂、技术可及性不足等问题。怀揣"把 科研成果实现技术转化，让科研成果造福患者"的初心，北芯生命自2015年成立起，聚焦多项"卡脖 子"技术，持续推动高端有源介入医疗器械的国产化进程。 （来源：经济参考报） 通过优化营运管理，北芯生命持续提升经营效率，2024年销售费用率与管理费用率分别下降约21个、26 个百分点；净利润亏损大幅收窄65%，剔除股份支付影响后趋近盈亏平衡。 作为中国本土心血管精准介入领域的医疗器械企业，北芯生命积极响应高质量"出海"战略，推动中国智 造高端医疗器械惠及全球患者。目前，核心产 ...

公司成立不到5年，已构建起涵盖AI诊断、高端创新器械及进口替代产品的梯度化管线，展现出优异 的以临床需求驱动的系统化创新能力。其全国唯一的脉动式介入左心室辅助装置等产品，具备重大的 临床价值。 "我们坚信，悦唯医疗凭借其扎实的临床根基、全面的产品矩阵及高效的转化能力，必将成长为心血 管器械领域的领军企业。本次投资旨在助力公司加速产品研发与市场拓展，共同推动中国高端医疗器 械的自主创新与产业化进程。" 打造更符合中国的一线临床应用心脏外科产品。 本文为IPO早知道原创 作者｜ 罗宾 微信公众号｜ipozaozhidao 据IPO早知道消息，近日，北京悦唯医疗科技有限责任公司（下称"悦唯医疗"）宣布完成近亿元B轮 融资，由倚锋资本领投，北商资本、渤海创富跟投，凯乘资本担任独家财务顾问。通过本轮融资赋 能，悦唯医疗将继续强化在心血管外科及其他外延领域的研发创新与市场渗透能力，持续巩固其领先 地位。 悦唯医疗创立于2021年9月，公司基于创始团队长期的临床经历，挖掘临床需求，同时结合相关领 域发展现状，研发多款全球首创、国内首创或填补市场空白的医疗器械。目前公司已自研冠脉外科、 重症及体外循环两大产品线，包含近10款 ...

Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. has submitted its IPO application to the Shanghai Stock Exchange for listing on the Sci-Tech Innovation Board, aiming to leverage the fifth set of listing standards, marking it as the first domestic company to have its ECMO system approved for market entry [1][2]. Financial Performance - Hanno Medical is experiencing rapid growth, with revenue projected to increase from 29.83 million yuan in 2023 to 49.31 million yuan in 2024, and 37.36 million yuan achieved in the first half of 2025. The company's losses have significantly narrowed from 341 million yuan in 2023 to 82.27 million yuan in the first half of 2025, indicating improved operational efficiency [2]. Fundraising and Investment - The company plans to raise 1.06 billion yuan through its public offering, which will be allocated to R&D centers, production bases, marketing network construction, and working capital, aligning with its long-term strategy and national policies promoting high-end medical equipment development [3]. Technological Innovation - Hanno Medical emphasizes independent innovation, having developed all key technologies in-house, maintaining a leading edge in the industry. The company has mastered seven core technologies and holds 38 authorized invention patents, establishing a strong competitive barrier [4]. Product Development - The core product, Lifemotion ECMO system, was approved for market entry in 2023, breaking foreign monopolies. It received EU CE MDR certification in early 2025, becoming the first domestic ECMO product to enter international markets [4]. Market Coverage - The company's products have been adopted by over 140 hospitals nationwide, including top-tier hospitals, and have achieved international orders in Europe, South America, and Africa, with ongoing product registration efforts in emerging markets [6][7]. Market Growth Potential - The ECMO industry is projected to grow significantly, with the Chinese market expected to expand from 960 million yuan in 2024 to 3.71 billion yuan by 2030, reflecting a compound annual growth rate of 25.2%. The global market is anticipated to reach 5.8 billion USD by 2035 [7]. Business Model - Hanno Medical has established a sustainable business model centered on "equipment first, consumables driven," ensuring predictable cash flow through the continuous consumption of high-value consumables associated with ECMO systems. This model is expected to replicate in broader international markets, contributing to long-term value [8].

Core Insights - The Chinese high-end medical device industry is experiencing accelerated innovation due to regulatory measures such as the expansion of the innovation review green channel and the introduction of the "ranking and leading" mechanism [1][2] - The number of approved innovative medical devices in China has reached a historical high, with 65 approved in 2024 and 45 in the first half of 2025, marking an 87.5% year-on-year increase [2] - The domestic high-end medical device sector is making progress in localization, particularly in medical imaging, but still faces challenges in foundational research and reliance on imported components [3][4] Regulatory Measures - The National Medical Products Administration (NMPA) has implemented special reviews for innovative medical devices that are domestically created, internationally leading, and clinically valuable [1][6] - The NMPA is enhancing its legal standards and increasing support for research and development to expedite the market entry of innovative products [1][6] - An expert consultation mechanism has been established to guide companies through the regulatory process, ensuring that innovative medical devices meet safety and efficacy standards [6][7] Industry Progress - The domestic supply chain for medical imaging has improved, with significant advancements in the independent research and production capabilities of core devices [2][3] - Nearly half of the innovative medical devices approved in the first half of 2025 were non-powered devices and in vitro diagnostic (IVD) products, indicating a shift towards more advanced materials and technologies [5] - The NMPA has launched innovation cooperation platforms for artificial intelligence and biomaterials to facilitate the development and approval of cutting-edge medical devices [4][5] Challenges and Opportunities - Despite advancements, the industry still faces "bottleneck" issues in foundational research, software development, and reliance on imported key components [3][4] - The market for high-end medical devices is characterized by high R&D costs and low short-term profitability, which deters other industrial players from entering the sector [4] - New technologies in artificial intelligence and biomaterials present opportunities for further innovation in high-end medical devices [3][5]

Core Insights - The approval of innovative medical devices in China has reached a historical high, with 323 devices approved to date, reflecting a significant acceleration in regulatory innovation and support for high-end medical device development [1][2][5] Regulatory Developments - The National Medical Products Administration (NMPA) has implemented special reviews for innovative medical devices that are domestically created, internationally leading, and clinically valuable, aiming to optimize the review process [1][2] - The NMPA plans to enhance the legal and standard framework, increase support for research and development, and improve the efficiency of reviews and approvals [1][2] Industry Trends - The number of approved innovative medical devices has been increasing annually, with a 87.5% year-on-year growth in the first half of 2025 [2] - The domestic medical imaging industry has seen improvements in the supply chain and production capabilities, with many mid-to-low-end products achieving domestic substitution [2][3] Challenges in Domestic Production - Despite advancements, there are still significant challenges in foundational research, software development, and reliance on imported key components [3][4] - The overall market share of domestic high-end medical imaging equipment remains low, indicating ongoing dependency on foreign technology [3][4] Strategic Initiatives - The NMPA has established innovation cooperation platforms for artificial intelligence and biomaterials to facilitate the transformation of research into practical applications [5] - The Ministry of Industry and Information Technology and the NMPA have announced initiatives to focus on key materials and technologies to enhance domestic production capabilities [5] Expert Consultation Mechanism - The NMPA has introduced an expert consultation mechanism to guide innovative medical device companies through the development and approval process, ensuring comprehensive understanding of cutting-edge technologies [7][8] - The expert consultation process includes a diverse pool of approximately 2,500 experts across various medical and technical fields to support the review and evaluation of innovative products [8][9] Focus Areas for Future Development - Future research in artificial intelligence medical devices is expected to concentrate on wireless diagnostics, digital therapies, brain-machine interfaces, and flexible wearable devices [6]

Group 1 - The company reported a revenue of 224 million yuan for the first half of 2025, representing a year-on-year growth of 12.80% [1] - The net profit attributable to shareholders reached 32.67 million yuan, with a significant year-on-year increase of 92.02% [1] - The net profit after deducting non-recurring gains and losses was 20.81 million yuan, showing a remarkable growth of 2157.4% year-on-year [1] Group 2 - The company achieved comprehensive commercialization breakthroughs in its three energy platforms: "Radiofrequency + Cryo + Pulsed Field Ablation (PFA)" [1] - The approval of the PFA product from the affiliated company, Shangyang Medical, completed the company's commercial landscape [1] - The company’s self-developed PulseMagic pressure pulse catheter is in the product registration approval stage, expected to be approved within 2025 [1] Group 3 - The company has established a strong position as a domestic leader in the electrophysiology field, with over 1,000 hospitals covered and more than 80,000 surgeries completed [2] - The company’s Magbot magnetic navigation catheter and PathBuilder adjustable guiding sheath were selected for the 2025 high-quality development project of the Pudong New Area biomedicine industry [2] - International market revenue grew over 40% year-on-year, with successful entries into markets in Mexico, the UK, and Rwanda [2]

Core Viewpoint - The medical device sector is experiencing significant activity, with several companies seeing substantial stock price increases following positive regulatory news and government support for domestic innovation [1][3]. Group 1: Company Performance - Companies such as Sainuo Medical and Zhonghong Medical have seen their stock prices surge, with Sainuo Medical rising by 20.01% to 17.03 and Zhonghong Medical increasing by 19.99% to 16.21 [2]. - Other notable performers include Yangpu Medical, which rose by 10.86%, and Shangrong Medical, which increased by 9.90% [2]. Group 2: Regulatory Developments - Sainuo Medical's subsidiary received breakthrough medical device designation from the FDA for its COMETIU self-expanding intracranial drug-coated stent system, marking a significant milestone in the treatment of intracranial atherosclerotic stenosis [3]. - The National Medical Products Administration has approved new measures to support the innovation of high-end medical devices, which will benefit domestic manufacturers [3]. Group 3: Market Opportunities - New government procurement policies will exclude EU companies from participating in medical device purchases over 45 million yuan, creating opportunities for domestic manufacturers [3]. - The focus on high-end medical equipment and diagnostic instruments is expected to enhance the competitiveness and market share of companies with independent R&D capabilities [3]. - Companies with international market presence are likely to benefit from accelerated growth opportunities as domestic medical device firms expand globally [3].

Group 1 - Suzhou Meichuang Medical Technology Co., Ltd. has completed a Series B financing round of over 100 million yuan, with participation from various institutions including Suzhou Venture Capital and Sequoia China [1] - The company has raised over 300 million yuan in total financing within five months, highlighting its status as a capital focus in the high-end medical device sector [1] - The founder, Liu Wenjing, has 30 years of experience in the peripheral vascular and tumor intervention fields, emphasizing the importance of mastering core technologies for long-term success [3][4] Group 2 - Meichuang Medical has successfully overcome the technical challenges associated with medical-grade ePTFE material, becoming the first domestic company to achieve large-scale production [4] - The company is focused on three main areas: peripheral vascular intervention, tumor intervention, and blood access maintenance, with a diverse product line including vascular/non-vascular stents and artificial blood vessels [4] - The ePTFE tubing and membrane materials have completed the National Medical Products Administration documentation, clearing a significant hurdle for market entry [5] Group 3 - The recent financing will primarily support clinical trials for core products such as TIPs stents and artificial blood vessels, promoting domestic alternatives [5] - Investors express confidence in Meichuang Medical's growth potential, citing the founder's extensive experience and the company's innovative breakthroughs in ePTFE materials [5][6] - The company aims to enhance treatment accessibility through its proprietary ePTFE technology, addressing clinical needs and reducing reliance on expensive foreign suppliers [4][6]